GWALINA (Linagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. It works by increasing incretin levels, which enhance insulin secretion and reduce glucagon release in a glucose-dependent manner. Linagliptin helps achieve effective glycemic control with a low risk of hypoglycemia and is weight neutral. It is suitable for once-daily dosing and can be used in patients with renal impairment without dose adjustment.